Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 4
483
Views
12
CrossRef citations to date
0
Altmetric
Short Communications

Network pharmacology uncovers anti-cancer activity of vibsane-type diterpenes from Viburnum odoratissimum

, , , , ORCID Icon, & show all
Pages 637-640 | Received 25 Jan 2019, Accepted 10 Feb 2019, Published online: 11 Mar 2019
 

Abstract

Vibsane-type diterpenes, the characteristic compounds of Viburnum odoratissimum, exhibited significant cytotoxicity in many cancer cells. To search for the potential target of vibsane-type diterpenes on lung cancer, we combined methods of network pharmacology prediction and experimental verification. 80 active ingredients, 23 potential targets and 39 related pathways were analyzed through constructing the compound-target network and target-pathway network, and the potential target (EGFR) and key pathway (PI3K/Akt) were identified. Vibsanol C, an isolated vibsane-type diterpene with excellent cytotoxicity against lung cancer cells was chosen for further confirmation. Molecular docking study and drug affinity responsive target stability (DARTS) approach further indicated that EGFR is a direct target of Vibsanol C. Moreover, mechanistic studies revealed Vibsanol C might affect PI3K/Akt pathway by Western blot analysis. In conclusion, this study successfully predicted and confirmed the potential target of Vibsane-type diterpenes on lung cancer.

Graphical abstract

Disclosure statement

The authors have declared that there is no conflict of interest.

Additional information

Funding

This work was supported by the National Natural Science Foundation under Grant (81703385).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.